Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 143

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 143
---

In accordance with our shareholders’ approval from August
2021, and in compliance with our compensation policy, each non-employee director is granted options to purchase 18,000 ordinary shares
of the Company on the date of our annual general shareholders meeting at which such director is elected or re-elected to the board. The
chairperson of our board is granted options to purchase 36,000 ordinary shares. These options vest over a period of one year, with 25%
of the options vesting at the end of each successive three-month period following the director’s appointment or re-appointment (as
applicable) by the general meeting of shareholders, subject to continued service through each vesting date. In the case of a director
who is elected to the Board for the first time, all of the options to purchase 18,000 ordinary shares shall vest following a one year
“cliff” - i. e., on the anniversary of the initial date of election.

All option grants to directors following the approval of our 2021
Share Incentive Plan by our shareholders (i. e., as of August 10, 2021), are subject to the terms of our 2021 Share Incentive Plan and
are granted at an exercise price equal to the average closing sales price per ordinary share on the TASE over the thirty trading day period
preceding the subject date (but not less than “fair market value” with respect to grantees subject to U. S. tax). All option
grants to directors prior to August 10, 2021, are subject to the terms of our 2013 Share Option Plan and were granted at an exercise price
equal to the higher of (i) the average closing price of our ordinary shares on the TASE during the 30 trading days prior to the date of
option allocation, plus 5% and (ii) the closing price of our ordinary shares on the TASE on the date of option allocation. All such options
expire 10 years following the date of grant thereof.

Information regarding the options to purchase our ordinary shares
(including number of options, exercise price and expiration date of all such options) held by each of our directors and executive officers
who beneficially owns our ordinary shares, after including ordinary shares underlying options held by them, which, as of March 17, 2024,
were exercisable or exercisable within 60 days, appears in the beneficial ownership table in Item 7. A